ArticleFrontiers in pharmacology2022

First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration.

Alaa Din Abdin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.